Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind comparison of 9MW0311 versus Prolia in postmenopausal osteoporosis at high fracture risk
CTR20243993Phase 3Completed
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 9MW0311 in postmenopausal osteoporosis, sponsored by Jiangsu T-mab Biopharma Co., Ltd.. Started Nov 2024; status: completed.
02
Drugs
9MW0311
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20243993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243993.